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Introduction
Stem cells have the ability to self-renew and to dif-
ferentiate along multiple lineages. During develop-
ment, stem cells divide to yield distinct subpopula-
tions giving rise to non-self-regenerating progenitors
with restricted differentiation potential, which finally
differentiate into functionally mature cells. After
birth, either stem cells or progenitor cells play central
roles in the maintenance, repair, and reconstitution of
tissues in response to homeostatic or regenerative
signals [1]. Because of these unique characteristics,
stem cells hold great therapeutic potential and have
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become one of most fascinating topics in biological
research. Adult stem cells have been defined in tis-
sues with high turnover, including skin and gut [2].
Recently, stem cells have also been identified in tis-
sues with low regenerative potential and turnover,
such as the brain [3] and the kidney [4]. The exis-
tence of pancreatic stem cells has been elusive
because specific markers for their identification are
not available. Hence, stem cell research in the pan-
creas has become one of the most controversial
issues in the diabetes field. The present review will
focus on the current knowledge of our understanding
of the existence of pancreatic stem/progenitor cells
and the factors important for their expansion.
The pancreas is composed of the exocrine and
endocrine tissues. The exocrine tissue is organized
into acini, which produce digestive enzymes, and
secretory ducts, which deliver enzymes produced by
pancreatic acinar cells into the duodenum. The
endocrine tissue (the pancreatic islets of Langerhans)
is composed of four different cell types, α, β, δ and
PP cells. These cells produce the hormones
glucagon, insulin, somatostatin, and pancreatic
polypeptide (PP), respectively [5, 6]. Under physio-
logical conditions, the pancreatic islets control blood
glucose homeostasis. Diabetes mellitus ensues as a
consequence of the body's inability to respond nor-
mally to high blood glucose levels. Type I diabetes
occurs when a person's immune system specifically
attacks and destroys the insulin-producing beta cells
of the pancreatic islets of Langerhans [7]. While rou-
tine insulin therapy can provide the patients with
their daily insulin requirement, optimal glucose lev-
els are not maintained and therefore leaving diabetics
susceptible to debilitating complications such as
hypoglycemia, retinopathy, and cardiovascular dis-
eases. An ideal therapy is the transplantation of func-
tional beta cells into diabetic patients to restore nor-
mal glucose regulation. This therapy has proven suc-
cessful clinically [8]. However, major difficulties
include the shortage of donor tissue and recurring
autoimmunity. Type II diabetes mellitus results from
either the inability of pancreatic beta cells to secret
sufficient insulin or development of a state of insulin
resistance in target tissues. Reduction of beta cell
mass is critical in the genesis of type II diabetes. In
type II diabetic subjects, the beta cell mass show a
40-60% reduction [9, 10]. Interestingly, the beta cell
mass changes seem to be specific for the beta cells,
because the non-beta cells mass (α, δ, and PP) were
unchanged [11]. Thus, cell engineering of non-beta
cells or the selective expansion of stem/progenitor
cells offer the greatest potential for the development
of an abundant source of functional beta cells to treat
the insulin deficiency wrought by diabetes.
Experimental models of adult
pancreatic regeneration
Evidence of the existence of a stem/progenitor cell in
the pancreas rests mainly on the phenomenon of islet
neogenesis, which can be experimentally induced.
Cellophane wrapping of the hamster pancreas
induces a trophic stimulus that leads to ductal prolif-
eration and the development of a new population of
beta cells that is capable of reversing streptozocin-
induced diabetes [12, 13]. Another model of regener-
ation is that of partial pancreatic duct ligation [14]. In
this model, the islet neogenesis occurs from ductal
complexs which have been considered a proliferating
stem-cell compartment. Other models of adult regen-
eration include partial pancretectomy [15, 16] in
which 85-90% of the pancreas is removed. In this
case, beta cell neogenesis was found in the remnant
pancreas. In addition, in the streptozotocin (STZ)
induced diabetes model, the STZ specifically
destroys the beta cells and induces the regeneration
of pancreas, especially in neonates [17, 18]. In addi-
tion, we have documented the continuous develop-
ment of new endocrine cells in the pancreas of inter-
feron-gamma (IFN-γ) transgenic mice, in which the
IFN-γ is expressed under the control of the human
insulin promoter. IFN-γ transgenic mice demonstrate
dramatic proliferation of epithelial cells and continu-
ous neogenesis of islet cells from a progenitor cell
population localized in the ducts through a process
similar to that occurring during embryonic islet mor-
phogenesis [19–21]. This model is therefore very
useful for studies of adult pancreatic regeneration.
Where do adult pancreatic stem
cells/progenitor cells exist?
The neogenesis of islets from duct epithelial cells
occurs during normal embryonic development
and in very early postnatal life [5, 22]. As noted
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above, the beta cell mass in the adult pancreas
possesses the ability to undergo limited regenera-
tion following injury. Therefore it is believed that
like other tissues, stem/progenitor cells must also
exist in the pancreas to participate the regenera-
tion and repair process. 
There is some evidence to suggest that pancreat-
ic stem/progenitor cells reside within pancreatic
ductal cells, where they can differentiate and
migrate to form new islets during both organogene-
sis and regeneration [20, 23]. In addition, endocrine
differentiation has been reported in human pancre-
atic duct cells [24, 25] and culture of mouse pancre-
atic ductal epithelial cells generated functioning
islets containing α-, β-, and δ- cells [26]. Indeed,
when these intro-generated islets were transplanted
into diabetic NOD mice, diabetes was reversed.
Furthermore, a recent study demonstrated that fetal
pancreatic ductal cells could differentiate into
insulin-producing cells [27]. Transplantation of the
pseudo-islets prepared from the beta cells derived
from ductal cells reversed STZ- induced diabetes in
nude mice. These data suggest that duct cells are a
source of pancreatic progenitor cells. While progen-
itors of insulin producing cells may exist in ductal
cells, duct cells have a differentiated phenotype,
and thus it is difficult to support the notion that they
are true stem cells. For this reason, people usually
recognize them as progenitor cells. 
There is also some support for the notion that
pancreatic stem/progenitor cells reside inside the
islet or acinar tissue. Guz et al has reported that
after administration of STZ, two kinds of presump-
tive progenitor cells exist inside the islets, one
expressing Glu-2 and the other expressing insulin
and somatostatin, suggesting the possibility that the
progenitor cells may exist inside the islet and might
potentially include the insulin-producing cell itself
[28]. A distinct population of nestin-positive cells
resides in the rat and human islets and has been
reported as hormone-negative immature cells that
are multi-potential and can proliferate extensively
in vitro and appear to be multipotent [29, 30].
Another study demonstrated that a population of
small cells that are positive for PDX-1, synapto-
physin, insulin, glucagon, somatostatin, pancreatic
polypeptide, alpha-fetoprotein and Bcl-2, but nega-
tive for cytokeratin 19 and nestin in human and
canine pancreas serve as progenitors contributing to
islet growth [31]. Insulin secretion studies demon-
strated that these cells secrete insulin in a glucose-
responsive fashion. Although this study does not
provide evidence of the proliferation and differenti-
ation potential of these fascinating cells, their
immature morphology, along with their small size
and quiescence has lead to the hypothesis that these
cells may serve as progenitors contributing to islet
growth. Furthermore, Suzuki et al indicated that a
possible pancreatic stem /progenitor cell candidate
that expresses the receptor for hepatocyte growth
factor (HGF) c-Met resides in the developing and
adult mouse pancreas. In adult these cells are
expressed in the duct as well as some of the acinar
cells. These cells form colonies in vitro and differ-
entiate into multiple pancreatic lineage cells from
single cells [32].
Pancreatic transdifferentiation - stem
cell plasticity
Traditionally, adult stem cells are thought to be
restricted in their potential to differentiate and
regenerate to the tissues in which they reside.
However, this concept has been changing due to
new evidence suggesting that adult stem cells not
only reside locally in specific niches, but may also
be recruited from the circulation to actively partici-
pate in the regeneration of various tissues. The abil-
ity of multipotential adult stem cells to cross lin-
eage boundaries and to give rise to cells not normal-
ly found in the organs or tissues of residence is
called transdifferentiation [33]. For example, bone
marrow stroma cells can generate skeletal muscle
[34] and neural stem cells can give rise to blood
cells [35] cardiac muscle [36] and oval hepatocytes
[37]. Transdifferentiation of adult ductal cells [24,
26], acinar cells [38–40] and even cells that do not
reside within the pancreas such as liver [41–44] and
intestine [45] have been suggested as an alternative
mechanism by which beta cell neogenesis can
occur. Adenovirus-mediated uptake of PDX-1 into
liver cells in vivo can induce a beta cell-like pheno-
type that produces sufficient biologically active
insulin to alleviate the hyperglycemia associated
with streptozotocin-induced diabetes in rats [46].
Liver cells that overexpress PDX-1 can become
pancreatic cells both in vitro and in vivo [42]. In
addition, oval cells (hepatic stem / progenitor cells)
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can differentiate into insulin-producing cells that
can reverse hyperglycemia in diabetic NOD-SCID
mice [41]. Recently, Kojima et al reported that
NeuroD-betacellulin gene therapy induces islet
neogenesis in the liver and reverses diabetes in
mice [44]. Previous studies have shown that activin
A and betacellulin (BTC) or hepatocyte growth fac-
tor (HGF) convert amylase-secreting pancreatic
AR42J cells into insulin-producing cells [38, 47],
whereas dexamethasone treatment can convert
AR42J cells and pancreatic cultures from mouse
embryo [48] and acinar cells into hepatocytes [49].
This transdifferentiation is associated with induc-
tion of the transcription factor C/EBP β
(CCAATenhancer binding protein) [48]. A recent
study also demonstrated that treatment with
leukaemia inhibitory factor (LIF) and epidermal
growth factor (EGF) can transdifferentiate exocrine
tissue into functional beta cells [50].
Besides the endodermal origin of transdifferenti-
ation, Ianus and colleague showed that bone mar-
row cells can serve as pancreatic stem cells [51].
Splenocytes can transdifferentiate into islet and
ductal epithelial cells within the pancreas where
they mature into fully functional islet cells respon-
sible for restoring normoglycemia [52]. However,
recent reports suggest that transdifferentiation is in
fact a cell fusion phenomenon. For example, adult
334
Fig. 1 A simple diagram depicting the possible mechanisms for pancreatic transdifferentiation. Cells from liver,
intestine, and pancreas have common progenitor cells in the endoderm during development. Upon stimulation by
cytokines or growth factors such as activins, HGF, EGF, TNF-α, or IFN-γ, or during islet injury, these cells can be
reprogrammed or dedifferentiated and then transdifferentiated. In addition, mature tissues, both in the endoderm and
in the mesoderm might harbor a small number of pluripotent stem cells that have more lineage plasticity to differ-
entiate into completely distinct phenotypes from that found normally in that tissue under specific circumstances.
murine bone marrow cells can fuse spontaneously
with embryonic stem cells [53], mouse neural pro-
genitor cells can fuse with pluripotent embryonic
stem cells [54] and cell fusion between adult stem
335
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Factors In vivo studies In vitro studies Reference
GLP-1
Stimulates the proliferation 
of β-cells and the differentiation 
of ductal progenitor cells.
Induces differentiation of pancreatic progenitor
cells into insulin-producing cells
72–76
Exendin-4
Stimulates the proliferation of
ductal progenitor cells and β-
cells.
Promotes the differentiation of insulin-positive
cells in ES cultures; induces the differentiation of





Regulate the growth and differentia-
tion of endoderm; induces the pro-
liferation of ductal and intra-islet
progenitor cells.
Stimulate proliferation of ductal epithelial
cells. 77–84
EGF
Expands the pool of embryonic
epithelial precursors; inhibit differ-
entiation of β-cells.
Stimulates the proliferation of ductal epithelial
cells. 82, 85–88
BTC
Regulates growth and differentia-
tion of fetal pancreas; promotes
neogenesis of β-cells from the
progenitors inside islets and the
ductal epithelial cells
Stimulates ductal cell growth, converting
AR42J cells into insulin-producing cells 38, 89–92
HGF
Promotes β-cell proliferation;
increases β-cell mass in fetal and
regenerating pancreas.
Promotes proliferation of pancreatic progeni-




Promote β-cell differentiation in
fetal pancreas and adult regenerat-
ing pancreas
Promotes the differentiation of insulin-positive
cells in ES cultures; Inhibits growth of AR42J
cells and converts AR42J cells into endocrine
cells; increases insulin-positive cells in ES cul-
tures.
27, 38, 47, 62,
99, 100
Follistatin
Promotes proliferation of pancreat-
ic progenitor cells in adult regener-
ating pancreas.
Promotes the growth of ductal progenitor
cells. 100
GDF11
Inhibits the endocrine progenitor
cell formation in embryonic pan-




Promotes the proliferation of duc-
tal progenitor cells. 
Stimulates ductal progenitor cell migration. 105
Conophylline
Induces differentiation of fetal
pancreas.
Induces differentiation of AR42J cells and
increases β-cell formation from progenitor
cells.
109, 110
Table 1 Factors regulating proliferation and differentiation of pancreatic progenitor cells.
n.d.: not determined
cells and epithelial cells is a frequent event [55]. In
vivo studies also suggest that transdifferentiation of
circulating hematopoietic stem cells (HSCs) is an
extremely rare event [33] and may be caused by cel-
lular fusion [56, 57]. However, in the study of Ianus
and colleagues, the bone marrow cells that selective-
ly express the reporter gene-enhanced green fluores-
cent protein (EGFP) under the control of insulin pro-
moter were transplanted in recipient mice and gave
rise to EGFP-positive insulin-producing cells in pan-
creatic islets. These bone marrow-derived cells
expressed islet related transcription factors and were
functionally responsive to glucose. Furthermore, by
using the CRE-LoxP reporter system, the authors
suggested that in vivo cell fusion is an unlikely expla-
nation for the "transdifferentiation" of bone marrow-
derived cells into differentiated cell phenotypes.
Another study also demonstrated that adult bone
marrow cells are capable of transdifferentiating into
a pancreatic lineage in vitro and transplantation of
these cells could correct the hyperglycemia in vivo
[58]. Mathews and colleagues, on the contrary,
reported that bone marrow-derived endothelial pro-
genitor cells (EPCs) are recruited to the pancreas in
response to islet injury and contribute to the survival
and function of islet, but there is no evidence of
transdifferentiation of bone marrow cells into
insulin-producing cells [59]. This suggests that the
improvement of beta cell function is induced by the
up-regulated neovascularization induced by EPCs. It
is clearly that the plasticity of bone marrow cells
needs to be clarified.
The mechanism of transdifferentiation is not
understood. One possibility might be that cells from
liver, intestine, and pancreas have common progen-
itor cells from the endoderm or adjacent area during
development, and upon certain stimulation, such as
tissue damage, cytokines, or growth factors, they
can be reprogrammed or dedifferentiated and trans-
differentiated into a completely distinct phenotype
which is found normally in that tissue. An alterna-
tive explanation might be that mature tissues harbor
a small number of pluripotent stem cells that have
more lineage plasticity than previously thought
(Fig. 1). Since not all of the cells in a given tissue
will transdifferentiate upon stimulation, we need to
clarify the characteristics of the cell subpopulation
sensitive to transdifferentiation. We also need to
determine if bone marrow or hepatocytes can trans-
differentiate into beta cells whether there are other
cell types of islet such as α cells, PP cells and δ
cells. Finally, we need to understand what factors
make cells from one tissue differentiate into a tissue
of a different type as well as what signals are nec-
essary for the transdifferentiation to be triggered.
Although many questions still need to be addressed,
transdifferentiation represents a valuable approach
to generate "self" surrogate beta cells that are suit-
able for replacing impaired islet cell function in dia-
betics. We can imagine that if cells from tissues out-
side of the pancreas can be to develop into insulin-
producing cells that are responsive to physiologic
signals, they will provide an additional source of
beta cells for transplantation.
In summary, islet stem/progenitor cells might
not only in the ductal epithelium but also within the
islets itself, and might even arise from exocrine aci-
nar cells or from cells outside of the pancreas which
posses remarkable plasticity to dedifferentiate and
transdifferentiate.
Differentiation of embryonic stem
(ES) cells into insulin-producing cells
The therapeutic potential of transplantation of
insulin-producing beta cells has stimulated interest
in using pluripotent embryonic stem (ES) cells to
generate insulin secreting cells in vitro. Studies
have shown that human ES cells can be differenti-
ated into insulin-producing cells in vitro and if this
method is further improved, may lead to the forma-
tion of an unlimited source of cells suitable for
transplantation [60]. Mouse ES cells can also be
differentiated into insulin-producing cells; expres-
sion of Pax-4 in mouse embryonic stem cells pro-
motes the differentiation of nestin-positive progen-
itor and insulin-producing cells, which lead to the
formation of islet-like clusters [61]. Cells in the
islet-like clusters show glucose-dependent insulin
release at their terminal stage. The authors also sug-
gested that nestin and cytokeratin 19 are normally
expressed by ES cells preceding differentiation into
C-peptide/insulin producing cells, whereas islet-
like clusters at the terminal stage are nestin-nega-
tive. Another study showed that mouse ES cells can
be directed to differentiate into insulin-producing
cells with the stimulation of activin B and exendin
4 [62], and transfection of Nkx6.1 can direct the
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differentiation of mouse ES cells into insulin-pro-
ducing cells [63]. These studies open a new avenue
for developing strategies to differentiate ES cells
into insulin-producing cells in vitro.
Like other emerging fields, stem cell research is
surrounded by controversies. A recent study sug-
gested that mouse ES cells readily differentiate into
extra-embryonic endoderm in vitro, raising the pos-
sibility that the insulin-producing cells might be
extra-embryonic endoderm rather than the assumed
authentic embryonic endodermal endocrine cells
[64]. Another report also showed that the
immunoreactivity to insulin results from the uptake
of exogenous insulin in vitro rather than from the
differentiated cells themselves [65]. In spite of
these reports, researchers are optimistic that embry-
onic stem cells provide a potential source for beta
cell replacement. If we can direct ES cells into
insulin-producing cells in vitro, and further lead
them form pseudo-islets, which are more efficient
for transplantation, an effective treatment diabetes
will be available to affected individuals.
Do pancreatic stem/progenitor cells
really exist in the adult pancreas?
A recent study raised a very critical question about
the existence of pancreatic adult stem cells. Using a
genetic lineage-marking technique, Dor and col-
leagues have demonstrated that beta cell turnover
under normal condition as well as during regenera-
tion induced by partial pancreatectomy results from
duplication of pre-existing beta cells themselves,
but is not the contributions of non-beta cells, such
as duct cells or "stem" cells. This challenges the
prevailing hypothesis in the research field of adult
pancreatic stem cells [66]. However, certain caveats
of the study are not addressed. The partial pancrea-
tectomy model used in this study showed only very
low regeneration and might not have been enough
to induce the pancreatic regeneration from a pan-
creatic stem cell population. A more efficient
method of pancreatic regeneration such as 90%
pancreatectomy or the IFN-γ transgenic model
might be better models for this study. Other con-
cerns with the study raised by Zaret is whether the
recombinase gene used is a little "leaky", producing
some marked non beta cells that escaped detection
[67]. Despite these concerns, this study by Dor et al
suggests that beta cells themselves might be the
optimal cell type for the generation of more beta
cells. If beta cells could be induced to replicate at a
higher rate, this might prove beneficial in maintain-
ing normoglycaemia, since the beta cell mass is a
major determinant of the total amount of insulin
that can be secreted by the pancreas. Therefore,
research on the proliferation of beta cells and the
molecular basis of beta cell replication should be
given more attention than ever before.
Regulation of expansion and
differentiation of pancreatic 
stem/progenitor cells
While the control of pancreas development by the
critical transcription factors is an active area of
research in many labs [68, 69], non-transcription
factors that control the proliferation and differenti-
ation of pancreatic progenitor cells are also attract-
ing researchers' attention. Understanding these fac-
tors will not only help to increase regeneration of
the progenitor cells themselves but will also be
applicable to the expansion of beta cell mass in
transplanted islets.
Glucagon-like peptide-1 (GLP-1) is an incretin
and is produced by the L-cells of the intestine [70].
GLP-1 has been reported to induce proliferation of
the insulinoma (INS-1) cell [71] and to stimulate
the differentiation and proliferation of beta cells in
the Goto-Kakizaki rat, a model of type II diabetes
[72]. GLP-1 increases beta cell mass by inducing
the differentiation and neogenesis of ductal progen-
itor cells into islet endocrine cells [73]. Exendin-4,
a long-acting GLP-1 agonist, stimulates both the
differentiation of beta cells from ductal progenitors
and the proliferation of beta cells in the pancreatec-
tomized adult rat [74]. In vitro studies also showed
that GLP-1 induces differentiation of islet PDX-1
positive pancreatic ductal cells into insulin-secret-
ing cells [75]. GLP-1 and exendin 4 convert pancre-
atic AR42J cells into glucagon-and insulin-produc-
ing cells [76]. 
Fibroblast growth factor (FGF) 10 was shown to
be capable of inducing the proliferation of the pan-
creatic epithelium in a direct fashion in vitro, and
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can therefore be used in amplifying the pool of pro-
genitor cells [77]. FGF10 is also reported to main-
tain the proliferative capacity of epithelial progeni-
tor cells during early pancreatic organogenesis [78].
Recent studies suggested that FGF10 stimulates
proliferation and blocks the differentiation of pan-
creatic epithelial cells [79, 80]. Keratinocyte
growth factor (KGF), also called FGF 7, is a mem-
ber of the heparin-binding fibroblast growth factor
family that has been demonstrated to enhance the
proliferation of pancreatic ductal cells in vivo [81].
Transgenic mice expressing KGF in their beta cells
showed increased ductal cell proliferation [82].
Furthermore, KGF is capable of inducing human
fetal beta cell expansion by activating ductal cell
proliferation and their subsequent differentiation
into beta cells. Hence, beta cell mass is increased in
transplanted human fetal pancreatic cells [83].
Another study also suggested that KGF and nicoti-
namide could induce the proliferation and differen-
tiation of intra islet precursor cells [84]. 
Epidermal growth factor (EGF) is induced in
the adult regenerating pancreas [85]. Over-expres-
sion of EGF in islet induces disorganized islet
growth [82]. EGF also stimulates ductal cell
growth in vitro [86]. EGF has the ability to expand
the pool of embryonic pancreatic epithelial precur-
sor cells, while it also suppressed their differentia-
tion into endocrine tissue [87]. Administration of
EGF/gastrin in diabetic mice significantly
increased beta cell mass and yeilded a greater num-
ber of BrdU labelled beta cells [88].
Betacellulin (BTC), a member of EGF family,
was originally isolated from an insulinoma cell line
[89]. BTC has been shown to play a role in regulat-
ing growth and differentiation of endocrine precur-
sor cells of the fetal pancreas [90] and to convert
amylase-secreting pancreatic AR42J cells into
insulin-producing cells [38]. BTC has also shown
to stimulate the regeneration of pancreatic beta cells
and induce the neogenesis of beta cells from pro-
genitors located in or by the pancreatic duct in ani-
mal models of diabetes [91]. Glucose metabolism
has also been improved by BTC, which promotes
the conversion of intra islet precursor cells to beta
cells in streptozotocin-treated mice [92].
Hepatocyte grwoth factor (HGF) has been
demonstrated to promote beta cell proliferation
and regeneration of fetal and adult islets [93–95].
Transgenic mice that overexpress HGF in islets
are resistant to the STZ-induced diabetes and have
enhanced beta cell proliferation and increased islet
mass [96]. Together with Activin A, HGF can
induce the differentiation of AR42J cells into
insulin-producing cells [47]. In vitro studies
showed that HGF promotes beta cell proliferation
with the support of a fibrin matrix [97]. Recent
studies demonstrated that HGF mediates differen-
tiation of immature cell types into insulin-express-
ing cells [98]. Together, the above data suggests
that GLP-1, exendin-4, FGFs, BTC and HGF are
useful to promote neogenesis of beta cells from
the progenitor cells inside the islets and pancreat-
ic ductal cells.
Activins, members of the transforming growth
factor-beta (TGF-β) superfamily, are important in
the differentiation of several distinct types of cells,
as well as in governing embryonic axial patterning
and the function of foregut-derived organs. Activin
A promotes beta cell differentiation in human fetal
pancreatic cells in the STZ induced diabetic mouse
[99]. Activin A converts AR42J cells into endocrine
cells [38, 47]. Treatment with activin A and BTC
coverts ductal cells from neonatal rats into insulin
producing cells [27]. We have demonstrated that the
expression of both activins and their receptors are
increased during adult pancreatic regeneration in
the IFN-γ mouse [100]. Interestingly, activins are
also up-regulated in duct cells following partial
pancreatectomy and streptozotocin (STZ) injection,
suggesting that activins might be involved in the
initiation of beta cell neogenesis following distinct
stimuli in adulthood [101, 102]. Of particular
importance, the cellular inhibitors of activin signal-
ing, such as follistatin [103] and Cripto [104] are
also present within a subset of the epithelial com-
partment. Administration of the natural antagonist
of activins, follistatin, enhanced duct cell expansion
in the regenerating pancreas. The proliferation of
epithelial duct cells was increased 1.8 fold com-
pared to the control transgenic mice. However, the
subsequent differentiation into pancreatic beta cells
was inhibited compared to that of the control mice.
These results demonstrated that homeostasis of
growth and terminal differentiation requires a pre-
cise context-dependent regulation of activin signal-
ing, and that follistatin participates in this process
by promoting expansion of precursor cells during
pancreas growth. These data also suggested that fol-
listatin might be useful for in vitro expansion of
338
pancreatic progenitor cells [100]. Therefore, elec-
tive blocking of activin signaling might be used in
the expansion of progenitor cells. Together with
other data, such as EGF [87] and FGF10 [79, 80]
which expand the pool of embryonic pancreatic
progenitor cells but at the same time inhibit
endocrine cell differentiation, we conclude that cell
proliferation might act as a repressor of endocrine
cell differentiation, raising the possibility that if we
can repress the differentiation of endocrine cells,
cell proliferation will be increased. The balance
between growth and differentiation of pancreatic
progenitor cells might therefore be controlled by
growth factors such as EGF, FGFs, Cripto, activin,
and follistatin (Fig. 2).
Other factors such as the stromal cell-derived
factor-1alpha (SDF-1alpha)/CXCR4 ligand-recep-
tor axis [105] is also critical for progenitor cell sur-
vival and migration. Vascular endothelial growth
factor (VEGF) is also known to stimulate ductal
cell replication and insulin production [106, 107].
Growth differentiation factor 11(GDF11), also
know as BMP11, recently was reported to negative-
ly regulate the production of pancreatic islet precur-
sor cells and is required for regulating islet size,
beta cell maturation, and beta cell mass [108].
Conophylline, a vinca alkaloid extracted from the
tropical plant Ervatamia microphylla, has been
reported to induce differentiation of pancreatic
AR42J cells [109] via a similar pathway to 
activin A. As it is a smaller molecule than the
activins, better penetration of tissues is expected.
Conophylline induces the differentiation of fetal rat
pancreas in organ culture and of pancreatic progen-
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Fig. 2 A schematic diagram for endocrine differentiation from ductal progenitor cells in the adult regenerating pan-
creas. The centroacinar and ductal cells in the top 3 panels are stained for the A subunit of activins (brown). The
centroacinar cells grow into small ducts, and the small ducts grow into large ducts, and the endocrine cells differ-
entiate from the progenitor cells residing in the duct cells. The balance between growth and differentiation is main-
tained by activins and follistatin, Cripto and other growth factors such as, EGF, HGF, BTC, FGFs and etc.
itor cells and increases the formation of beta cells
both in vitro and in vivo [110]. This suggests that
Conophylline may be useful for the promotion of
differentiation of pancreatic progenitor cells. Table
1 summarizes recent studies on the factors that are
important for the expansion and differentiation of
pancreatic progenitor cells.
While many factors have been shown to be
important for the growth and differentiation of pan-
creatic progenitor cells, the relationships between
these factors and transcription factors important for
the development of pancreas are poorly understood.
GLP-1 is known to stimulate the growth and differ-
entiation of beta cells by inducing the expression of
the pancreatic and duodenal homeobox gene
(PDX1) which is required for pancreas develop-
ment [73]. Exendin-4 induces the differentiation of
human pancreatic duct cells into endocrine cells by
activating adenylyl cyclase and MAP kinase activi-
ty which, in turn, might lead to activation of PDX-
1 and HNF3b [111]. We have previously reported
that the expression of transcription factors Pax4
[112] and neurogenin 3 (Ngn 3) [113], which are
critical for islet development, were induced and sig-
nificantly increased during the differentiation of
AR42J cells by activin and HGF. Activin A there-
fore regulates the expression of neurogenin 3 that is
critical for the differentiation of AR42J cells [114].
In addition, in probing the mechanism by which
KGF induces differentiation of ductal precursor
cells into beta cells, Movassat et al suggested that
the mechanism of KGF on differentiation might be
partially through the stimulation of activin expres-
sion [83]. This was based on the previous work
showing that KGF upregulated the expression of
activin A in skin [115]. It is clear that further stud-
ies on these important subjects will open a wider
avenue for our understanding of the mechanism of
differentiation and expansion of pancreatic progen-
itor cells.
Conclusion and perspectives
Because of its great therapeutic potential, stem cell
research has become one of the most promising
fields in biomedical research today. Despite the
conflicts and difficulties encountered in this area of
research, the possibility that insulin-producing
cells can be induced in vitro inspires us to deepen
our understanding of basic stem cell biology.
Reports outlined in this review enumerate exam-
ples of the identification and expansion of adult
pancreatic stem/progenitor cells. At the moment,
however, we understand very little about the regu-
latory mechanisms and the signaling pathways that
direct the balance between growth and differentia-
tion. Further studies in this area will have an
impact on our understanding of stem/progenitor
cell differentiation. Conditions that activate the
proliferation and differentiation of stem/progenitor
cells in the central nervous system have been iden-
tified [116]. We are optimistic that with all of these
models of pancreatic regeneration in adults, and
the enthusiastic efforts of researchers in the dia-
betes field, this goal will be achieved in the near
future. 
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